ssri sexual side effects — the numbers nobody gave you

it works. your mood is better. and something that used to be part of your life is just gone — desire, sensation, the ability to finish, sometimes all three. you probably have not told your prescriber, because the appointment is fifteen minutes and this is the hardest sentence in it.

here is what the research actually found, including the parts that are unresolved and the parts paid for by the company selling the fix.

how common this is, when someone actually asks

the reason your experience does not match the leaflet is measurement. when sexual function is actually asked about with a questionnaire, rather than waited for as a spontaneous complaint, a meta-analysis found treatment-emergent sexual dysfunction in 25.8% to 80.3% of patients depending on the drug — every one of them significantly above placebo^[1].

in that analysis the drugs ranked, from most sexual dysfunction to least: sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram, fluvoxamine. six drugs showed no significant difference from placebo — agomelatine, amineptine, bupropion, moclobemide, mirtazapine and nefazodone^[1].

the range is that wide partly because the pooled studies used different scales and some were open-label. the authors say so themselves. what the spread does not do is make this rare.

what the trials found for staying on the drug

the best synthesis is a Cochrane review of 23 randomised trials in 1,886 people^[2]. what it found:

• sildenafil in men (3 trials, 255 men) and tadalafil in men (1 trial, 54 men) improved erectile function more than placebo.
• sildenafil in women — the reviewers concluded it remains uncertain whether it beats placebo.
• bupropion 150 mg twice daily beat placebo on rating-scale scores across three trials (SMD 1.60, 95% CI 1.40 to 1.81). the same drug at 150 mg once daily did not (RR 0.62, 95% CI 0.09 to 4.41) — though that once-daily interval is so wide it settles nothing on its own.
• every other augmentation strategy tested failed.
• only one trial studied switching antidepressant. no trial tested psychological approaches. no trial tested drug holidays.

that last line is the part worth sitting with. the two things people are most often told to try — switch drugs, take a weekend off — are almost entirely untested in randomised trials.

the review also has a conflict you should know about: two of its six authors declare financial ties to the makers of the two drugs it endorses. one has consulted for Pfizer, which makes sildenafil; another has taken lecture fees from Bristol-Myers Squibb and has a spouse employed by GlaxoSmithKline, which makes bupropion^[2]. the funding was public. the disclosures are not clean. both facts are true at once.

the sildenafil trials, and who paid for them

in 90 men whose depression was in remission on a serotonin reuptake inhibitor but who had drug-associated sexual dysfunction, six weeks of sildenafil produced much or very much improvement in 54.5% (24 of 44) versus 4.4% (2 of 45) on placebo, and depression scores stayed in remission in both arms^[3]. it is six weeks and 90 men, so it says nothing about long-term use, and it was funded by an investigator-initiated grant from Pfizer, which makes the drug.

in 98 premenopausal women in the same situation, eight weeks of sildenafil beat placebo on the clinician-rated sexual function scale by 0.8 points (95% CI 0.6 to 1.0), shrinking to 0.6 points once the 22% who dropped out early were counted as unchanged. headache, flushing and indigestion were frequent^[4]. it is the only positive trial of its kind in women, Pfizer funded it and supplied the drug, and the Cochrane review still calls the question unsettled^[2].

the part nobody can answer: does it stop when the drug stops

on 16 May 2019 the European Medicines Agency’s safety committee ordered every manufacturer of citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine and milnacipran to add a warning to the product information within two months^[5]. the wording it required:

“There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.”

the patient leaflet version is plainer: “In some cases, these symptoms have continued after stopping treatment.”^[5]

read that for exactly what it is. a regulator acted on adverse-event reports, published literature, social media and manufacturer reviews — not on a prevalence study. so how often this happens is unknown, and the uncertainty cuts both ways: it is not evidence that it is common, and it is not permission to tell someone it is imaginary. two further details from the same document: clomipramine and vortioxetine were part of the signal assessment but were deliberately left out of the labelling requirement, and US labelling carries no equivalent wording — so an American leaflet may say nothing at all about this.

where the evidence simply runs out

• nobody knows how many people get symptoms that persist after stopping.
• within the 23 trials the Cochrane review pooled, exactly one studied switching antidepressant^[2].
• within the same 23, none tested a psychological approach and none tested drug holidays^[2].
• the strongest positive results in women come from a single industry-funded trial that the relevant Cochrane review declines to endorse.

the honest summary: this is very common, there is real evidence for two add-on options in men, thinner evidence in women, and a regulator-acknowledged possibility that it does not always stop when the drug does.

what to take to your prescriber

the point of the numbers above is that you do not have to introduce this subject as a confession. you can introduce it as a question.

• where does the drug i am on sit on that ranking, and is there one with a lower rate that would still treat my condition?
• if i want to stay on this drug, is adding sildenafil or twice-daily bupropion an option for me?
• european regulators require a warning that these symptoms can persist after stopping — how would you and i tell that apart from the depression itself?
• if we change anything, how would we do it, and what should i watch for?

if the drug is not the whole story — if desire went first and the mood came after — the hub page covers what the research says about low libido and depression running in both directions, and about sexual performance anxiety, which turns out to have almost no treatment evidence at all.